BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 38468837)

  • 1. Reemergence of Splenectomy for ITP Second-line Treatment?
    Chater C; Terriou L; Duhamel A; Launay D; Chambon JP; Pruvot FR; Rogosnitzky M; Zerbib P
    Ann Surg; 2016 Nov; 264(5):772-777. PubMed ID: 27741009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
    Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
    Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center.
    Jaime-Pérez JC; Aguilar-Calderón P; Jiménez-Castillo RA; Ramos-Dávila EM; Salazar-Cavazos L; Gómez-Almaguer D
    Ann Hematol; 2020 Nov; 99(11):2513-2520. PubMed ID: 32945941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus Splenectomy in Chronic Primary ITP: Experience of a Single Hematology Clinic.
    Shamoon RP; Yassin AK; Alnuaimy SL
    Mediterr J Hematol Infect Dis; 2024; 16(1):e2024019. PubMed ID: 38468837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ITP and international guidelines: what do we know, what do we need?
    Rodeghiero F; Ruggeri M
    Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F
    Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with refractory immune thrombocytopenic purpura.
    George JN
    J Thromb Haemost; 2006 Aug; 4(8):1664-72. PubMed ID: 16879206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for children with immune thrombocytopenia: a systematic review.
    Liang Y; Zhang L; Gao J; Hu D; Ai Y
    PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of immune thrombocytopenic purpura in children : current concepts.
    Shad AT; Gonzalez CE; Sandler SG
    Paediatr Drugs; 2005; 7(5):325-36. PubMed ID: 16220997
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.